GSK-2126458
GSK-2126458 Basic information
- Product Name:
- GSK-2126458
- Synonyms:
-
- GSK2126458
- GSK-2126458
- GSK2126458; GSK-2126458
- 2,4-Difluoro-N-[2-methoxy-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl]benzenesulfonamide
- GSK2126458 (HYR-582)
- CS-55
- Omipalisib GSK2126458
- HYR-582
- CAS:
- 1086062-66-9
- MF:
- C25H17F2N5O3S
- MW:
- 505.5
- EINECS:
- 629-873-1
- Product Categories:
-
- Akt
- mTOR
- Aromatics
- PI3K/Akt/mTOR
- Inhibitors
- PI3K
- Heterocycles
- Intermediates & Fine Chemicals
- Pharmaceuticals
- Sulfur & Selenium Compounds
- Mol File:
- 1086062-66-9.mol
GSK-2126458 Chemical Properties
- Melting point:
- 187-189℃
- Boiling point:
- 715.6±70.0 °C(Predicted)
- Density
- 1.45
- storage temp.
- Refrigerator
- solubility
- Chloroform (Slightly), DMSO (Slightly), Methanol (Very Slightly, Heated)
- form
- Solid
- pka
- 6.23±0.40(Predicted)
- color
- White to Pale Yellow
GSK-2126458 Usage And Synthesis
Description
GSK2126458 is a potent inhibitor of phosphoinositide 3-kinase isoforms (Kis = 19, 130, 24, and 60 pM for p110α, β, δ, and γ, respectively). It also inhibits mTOR in both mTORC1 and mTORC2 (Kis = 180 and 300 nM, respectively), as well as several common mutant forms of p110α. GSK2126458 is orally bioavailable, displays favorable pharmacokinetics, and shows efficacy in tumor growth models. GSK2126458 positively combines with inhibitors of discoidin domain receptor 1 (DDR1) inhibitor DDR1-IN-1 to suppress the growth of SNU-1040 colorectal cancer cells.
Uses
A highly potent inhibitor of PI3K and the mammalian target of Rapamycin.
Definition
ChEBI: Omipalisib is a member of the class of quinolines that is quinoline which is substituted by pyridazin-4-yl and 5-[(2,4-difluorobenzene-1-sulfonyl)amino]-6-methoxypyridin-3-yl groups at positions 4 and 6, respectively. It is a highly potent inhibitor of PI3K and mTOR developed by GlaxoSmithKline and was previously in human phase 1 clinical trials for the treatment of idiopathic pulmonary fibrosis and solid tumors. It has a role as an autophagy inducer, an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor, a mTOR inhibitor, an antineoplastic agent, a radiosensitizing agent and an anticoronaviral agent. It is a member of quinolines, a difluorobenzene, a sulfonamide, an aromatic ether, a member of pyridines and a member of pyridazines.
target
p110α
storage
Store at -20°C
GSK-2126458Supplier
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- sales@boylechem.com
- Tel
- 010-82848833 400-666-7788
- jkinfo@jkchemical.com
- Tel
- +86-21-20908456
- sales@BioChemBest.com
- Tel
- 13817811078
- sales@jingyan-chemical.com
GSK-2126458(1086062-66-9)Related Product Information
- daprodustat,GSK1278863
- GSK1940029
- GSK 189254A
- GSK2110183
- gsk2200150a
- 4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
- 4-Methoxy-N-(2,4,6-triMethylphenyl)benzenesulfonaMide, 97%
- AZD-3965
- GSK1292263
- 7Methyl-5-(1-{[3-(trifluoroMethyl)phenyl]acetyl}-2,3-dihydro1Hindol-5-yl)7Hpyrrolo[2,3d]pyriMidin-4-aMine
- GSK-3beta Inhibitor XXVI(GSK-3b)
- Cadmium sulfide
- AZD-8055
- MK-2206 2HCl
- Pictilisib
- Erlotinib hydrochloride
- LY 294002 HYDROCHLORIDE
- Danirixin